ADVANCED chronic liver disease (ACLD) remains a major cause of illness and death worldwide, with prevention of disease progression a central goal of care. A recent review highlights how beta-blockers, particularly carvedilol, are being used to manage portal hypertension (PH) in ACLD, with potential to reduce first decompensation in patients with clinically significant PH.
ACLD describes severe liver damage, often including cirrhosis, where ongoing injury causes fibrosis and impaired function. It affects 1.3% of the global population. Many patients remain asymptomatic in early stages, but progression to decompensation – marked by complications such as ascites, variceal bleeding, or hepatic encephalopathy – significantly increases mortality risk.
Targeting Portal Hypertension in Advanced Liver Disease
PH, or increased pressure in the liver’s blood vessels, is the main driver of complications in ACLD. Managing this pressure is therefore a key therapeutic aim. Beta-blockers reduce portal pressure by lowering cardiac output and altering blood flow within the liver. Clinical trial data show they can reduce the likelihood of a first decompensation event in patients with clinically significant PH, particularly by decreasing the incidence of ascites. Their use is generally limited to this group, as evidence supporting benefit in patients without clinically significant PH remains lacking.
Carvedilol Shows Stronger Haemodynamic Effects
Among non-selective beta-blockers, carvedilol demonstrates a greater reduction in hepatic venous pressure gradient than propranolol. Evidence from clinical studies summarised in the review shows that carvedilol reduces hepatic venous pressure gradient more effectively than propranolol and may help delay first decompensation. Its profile appears more favourable than propranolol in later stages, although the overall effect of beta-blockers diminishes once decompensation occurs.
Treatment Depends on Disease Stage
The effectiveness and safety of beta-blockers vary across the course of ACLD. In compensated disease, they are generally well tolerated, although some patients do not respond and predictors of response remain unclear.
In decompensated disease, a ‘therapeutic window’ has been described. As cardiovascular function declines, particularly in patients with low blood pressure, kidney impairment, or refractory ascites, the balance of benefit and risk may change.
Combining Therapies and Wider Care
Beta-blockers are used alongside other approaches. Endoscopic variceal ligation is an alternative for those who cannot tolerate medication and is routinely used after bleeding events. A trial reviewed in the article found that combining carvedilol with endoscopic variceal ligation may reduce bleeding and mortality in higher-risk patients, although meta-analyses show results are inconsistent.
Beyond pharmacological treatment, managing underlying causes such as alcohol use, viral hepatitis, and metabolic disease is essential. Preventive measures including vaccination, nutritional support, and regular imaging also contribute to care.
Looking Ahead
Other therapies, including statins, anticoagulants, and treatments targeting metabolic liver disease, are under investigation. While some show haemodynamic or biological effects, consistent reductions in clinical outcomes have not yet been established according to current review evidence.
Overall, the findings laid out in this review support a stage-specific, multidisciplinary approach to ACLD, where beta-blockers are integrated with other strategies to help delay first decompensation and improve patient outcomes, particularly as clinically significant PH is closely linked to the risk of decompensation.
Reference
Süffert LC et al. Preventing First and Further Decompensation in Advanced Chronic Liver Disease. Liver int. 2026;DOI:10.1111/liv.70568.
Featured image: Andrii on Adobe Stock
